- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab .
|Active Phase 2 study NCT01941537.|
||Completed Phase 1 trial for psoriasis (see NCT00563524).|
|Completed Phase 2 trial for RA (see NCT00883896).|